Payment overview · 2025
General Payments
$342.75
8 reported records · 4 companies
Healthcare provider profile · identity verified
Arthur Mines, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MILWAUKEE, WI · NPI 1851438584
Verified facts
What the public records show
CMS Open Payments records show Arthur Mines, M.D. received $342.75 in general payments during 2025 across 8 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $138.58 | 40.4% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.99 | 36.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.41 | 18.2% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.77 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $342.75 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $138.58 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $62.41 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $62.41 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $62.41 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $16.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 537 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 459 | 129 |
| Potassium Chloride | Potassium Chloride | 221 | 64 |
| Lisinopril | Lisinopril | 195 | 56 |
| Metformin Hcl | Metformin Hcl | 192 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 178 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 56 |
| Simvastatin | Simvastatin | 176 | 47 |
| Gabapentin | Gabapentin | 168 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 36 |
| Omeprazole | Omeprazole | 153 | 40 |
| Allopurinol | Allopurinol | 148 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 140 | 34 |
| Losartan Potassium | Losartan Potassium | 130 | 43 |
| Linzess | Linaclotide | 128 | 30 |
| Furosemide | Furosemide | 123 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 32 |
| Ibuprofen | Ibuprofen | 112 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 25 |
| Jardiance | Empagliflozin | 93 | 20 |
| Metformin Hcl Er | Metformin Hcl | 90 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 70 | 19 |
| Montelukast Sodium | Montelukast Sodium | 68 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 23 |
| Naproxen | Naproxen | 62 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 14 |
| Nifedipine Er | Nifedipine | 59 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 58 | suppressed |
| Glipizide | Glipizide | 57 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 12 |
| Carvedilol | Carvedilol | 53 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 24 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 52 | 42 |
| Spironolactone | Spironolactone | 51 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 20 |
| Pregabalin | Pregabalin | 47 | suppressed |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Atenolol | Atenolol | 46 | suppressed |
| Alprazolam | Alprazolam | 44 | suppressed |
| Chlorthalidone | Chlorthalidone | 42 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 11 |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 18 |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Ibu | Ibuprofen | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Eliquis | Apixaban | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Mitigare | Colchicine | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $342.75 · 8 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, BREZTRI, COMIRNATY, PREVNAR 20, VOQUEZNA, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Zenpep play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error